

Company presentation

DNB Nordic Healthcare Conference
December 15th, 2020

Hilja Ibert, CEO

gentian



Important notice

This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The information herein and any other material discussed is subject to change.

The presentation contains certain forward-looking statements relating to the business, future financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, “expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”, “anticipates”, “targets”, and similar expressions. Any forward-looking statements contained herein, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Potential investors are expressly advised that financial projections, such as the revenue and cash flow projections contained herein, cannot be used as reliable indicators of future revenues or cash flows. Neither the Company (nor any of its parent or subsidiary undertakings) or the Managers (or any such person’s representatives, officers, employees or advisors) provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. No obligation is assumed to update any forward-looking statements or to conform these forward-looking statements to our actual results.

The distribution of this presentation may also in other jurisdictions be restricted by law. Accordingly, this presentation may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations. The Company require persons in possession of this presentation to inform themselves about, and to observe, any such restrictions.

Nothing in this presentation shall constitute an offer to sell or a solicitation of an offer to buy any shares in the Company in any jurisdiction in which such offer or solicitation is unlawful.

Nothing contained in this presentation is or should be relied upon as a promise or representation as to the future. Except where otherwise expressly indicated, this presentation speaks as of the date set out on its cover. In addition, no responsibility or liability or duty of care is or will be accepted by the Company for updating this presentation (or any additional information), correcting any inaccuracies in it which may become apparent or providing any additional information.

The logo for Gentian, featuring the word "gentian" in a bold, blue, sans-serif font. The letter "g" is stylized with a horizontal line through its middle. The logo is positioned in the bottom left corner of the slide.


gentian

Gentian Diagnostics – Corporate Overview

- Dedicated to the laboratory diagnostics market with focus on the immunochemistry segment
- Headquarter in Moss, Norway
- Offices in Sweden, China and the US
- 50 employees globally
- On Euronext Growth Oslo since December 2016



Source: Euronext Oslo Børs (share price data)



We innovate diagnostic efficiency

Strategy for sustainable double-digit sales growth



- One new product per year
- Competitive conversions
- Increased market demand due to positive clinical impact

GCAL[®] Calprotectin immunoassay

Early detection of
severe bacterial
infections, sepsis and
inflammation

gentian





NT-proBNP

(earlier referred to as G-1001)

First cardiovascular test for
high-throughput clinical
chemistry analysers

gentian



Sales model



**Global
Diagnostics Companies**
- OEM partnerships to secure broad
roll-out and acceptance of product

gentian




Distributors
- In selected markets we do not
serve directly



Healthcare providers
- Key relationships and larger
institutions in selected markets



Financial performance YTD per Q3 2020



Main achievements in 2020

- Achieved 36% sales growth per Q3 in a challenging market
- Successful launch of fPELA
- New scientific publications supporting GCAL[®] as an infection marker and most recently as a promising biomarker for predicting severity of disease for COVID-19 patients
- NT-proBNP is on track for the launch by end of 2021, including the establishment of a Scientific Advisory Board
- Initiated the development of a SARS-CoV-2 Ab assay, aimed for launch in 2021
- Divestiture of PreTect
- Strengthened management team with experienced talents from the industry



Get in touch with us

www.gentian.com – info@gentian.com

HQ GENTIAN AS

Bjørnåsveien 5, 1596 Moss, Norway

GENTIAN DIAGNOSTICS AB

Kungsgatan 8, 111 43 Stockholm, Sweden

GENTIAN USA INC.

215 N Eola Dr, Orlando, Florida US

BEIJING REP. OFFICE

Chaoyangmen Outer St Jia No.10
Chaoyang District, Beijing, China

